Name | Canertinib dihydrochloride |
Description | Canertinib dihydrochloride (PD-183805 dihydrochloride) is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities. |
Kinase Assay | Kinase inhibition: Cediranib is dissolved in DMSO at a concentration of 10 mM. All enzyme assays are run at, or just below, the respective Km for ATP (0.2 - 30 μM). The inhibitory activity of Cediranib is determined against a range of recombinant tyrosine kinases [KDR, Flt-1, Flt-4, c-Kit, PDGFRα, PDGFRβ, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aurora A, and Aurora B] using ELISA. Selectivity versus CDK2 and CDK4 serine/threonine kinases is examined using scintillation proximity assays with a retinoblastoma substrate and [γ-sup>33P]ATP. Activity of Cediranib is compared to MAPK kinase (MEK), which shows dual specificity. It is determined using a MAPK substrate, [γ-33P]ATP, and paper capture/scintillation counting. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 55.9 mg/mL (100 mM)
|
Keywords | ErbB-1 | PD 183805 | PD 183805 Dihydrochloride | Orthopoxvirus | PD-183805 | EGFR | Canertinib dihydrochloride | CI 1033 Dihydrochloride | PD183805 Dihydrochloride | PD183805 | CI1033 Dihydrochloride | Epidermal growth factor receptor | CI 1033 | PD-183805 Dihydrochloride | Inhibitor | CI1033 | inhibit | HER1 | CI-1033 | Canertinib Dihydrochloride | CI-1033 Dihydrochloride |
Inhibitors Related | Osimertinib | Lapatinib | Erlotinib | Gefitinib |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |